
A new report offers insights from a multidisciplinary team of experts on intrahepatic cholangiocarcinoma (iCCA).
Jared is a freelance writer for The American Journal of Managed Care® (AJMC®), and previously worked as a senior editor for HCPLive® at MJH Life Sciences®.
He has an MA from University of Sioux Falls. You can connect with Jared on LinkedIn.
A new report offers insights from a multidisciplinary team of experts on intrahepatic cholangiocarcinoma (iCCA).
A case report shows the potential of hepatopancreatoduodenectomy for certain patients who might otherwise be thought to have unresectable tumors
Health care providers can help alleviate caregiver burdens by teaching coping strategies, the authors said.
This ratio could be used to better predict disease activity and poor prognosis.
Investigators found significant shifts in diagnosis of and prescriptions for pulmonary hypertension (PH) when exercise right heart catheterization was used.
Patients were more likely to accept intervention from a psychologist if they received regular questionnaires.
The therapy for intrahepatic cholangiocarcinoma (ICC) led to responses in about a quarter of patients and disease control in 85%.
Elevated levels of HER2, VCAM, and TWEAK indicated proteinuria, study authors say of their new findings.
Investigators said they were able to confirm diagnoses of systemic lupus erythematosus (SLE) and thrombotic thrombocytopenic purpura (TTP) because they took a multidisciplinary approach.
New data show the stark contrast between untreated infants with type 1 spinal muscular atrophy (SMA) and those who received risdiplam.
Still, investigators say there are gaps in spinal muscular atrophy (SMA) screening protocol that need to be filled.
New real-world evidence on non–small cell lung cancer (NSCLC) aligns with the results of a 2017 clinical trial.
The combination is approved to treat hepatocellular carcinoma (HCC), but this case report suggests it can also work for combined HCC and cholangiocarcinoma (CHC).
Investigators say recent research into the development of cutaneous lupus erythematosus has created the potential for new therapies.
Investigators say classification based on magnetic resonance imaging can predict a patient’s risk of recurrence for intrahepatic cholangiocarcinoma (iCCA).
More people are eligible for screening, but a new analysis suggests lung cancer disparities are due to more than eligibility status.
The study also found broad tolerability, with 98% of patients remaining on the therapy after 12 months.
Clinical trials and targeted agents do not appear to affect health care–related quality of life, however.
A new case report highlights the difficulties in pinning down spinal muscular atrophy (SMA) when it presents in a mild form.
A new study highlights potential therapies to decrease cardiovascular risk in people with systemic lupus erythematosus (SLE) and identifies biomarkers that may indicate a heightened risk.
A patient who failed to respond to rituximab and steroids later saw dramatic improvement with sutimlimab
The research may eventually help clinicians optimize therapy with immune checkpoint inhibitors.
A new review article notes efforts to diagnose cholangiocarcinoma (CCA) early are hampered by a lack of biomarkers.
The technique outperformed physical examinations in identifying muscle fasciculations, which are common in spinal muscular atrophy (SMA).
A new study outlining the experiences of women with systemic lupus erythematosus (SLE) finds many women feel their initial symptoms are downplayed by providers, leading to costly delays in diagnosis.
Two studies showed how hospital-based trigger systems could help guide patients toward appropriate goals of care and in some cases palliative care.
Patients with cold agglutinin disease (CAD) had durable responses at week 53, and no new safety signals were reported.
New data suggest motor function improves with amifampridine.
A new review notes advances and remaining questions, and calls for better incorporation of data from veterans.
The tool could help clinicians better screen patients for adjuvant chemotherapy following curative resection for intrahepatic cholangiocarcinoma (ICC).
259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512
© 2025 MJH Life Sciences®
All rights reserved.